alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › estimating

estimating

2 studies tagged estimating, dated 2026-06-01 to 2026-10-14. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France 2026-10-14
  2. Estimating the time course of biomarker changes in Alzheimer's disease 2026-06-01

Studies

2 studies carry this tag.

Date range

2026

Top journals

  • Brain : a journal of neurology 1
  • The journal of prevention of Alzheimer's disease 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. The journal of prevention of Alzheimer's disease 2026-10-14 Treatments

    Lecanemab was the first amyloid-targeting monoclonal antibody approved by the European Commission for treating patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD).

  2. Estimating the time course of biomarker changes in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. Brain : a journal of neurology 2026-06-01 Biomarkers

    Recent advancements in biomarkers have transformed Alzheimer's disease (AD) diagnosis from being purely symptom-based to include biological criteria.

All topic tags with their study counts